Journal
SCIENTIFIC REPORTS
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-019-52270-x
Keywords
-
Categories
Funding
- Project for Development of Innovative Research on Cancer Therapeutics (P-Direct)
- Project for Cancer Research and Therapeutic Evolution (P-CREATE)
Ask authors/readers for more resources
Positron emission tomography (PET) imaging can assist in the early-phase diagnostic and therapeutic evaluation of tumors. Here, we report the radiosynthesis, small animal PET imaging, and biological evaluation of a L-type amino acid transporter 1 (LAT1)-specific PET probe, F-18-FIMP. This probe demonstrates increased tumor specificity, compared to existing tumor-specific PET probes (F-18-FET, C-11-MET, and F-18-FDG). Evaluation of probes by in vivo PET imaging, F-18-FIMP showed intense accumulation in LAT1-positive tumor tissues, but not in inflamed lesions, whereas intense accumulation of F-18-FDG was observed in both tumor tissues and in inflamed lesions. Metabolite analysis showed that F-18-FIMP was stable in liver microsomes, and mice tissues (plasma, urine, liver, pancreas, and tumor). Investigation of the protein incorporation of F-18-FIMP showed that it was not incorporated into protein. Furthermore, the expected mean absorbed dose of F-18-FIMP in humans was comparable or slightly higher than that of F-18-FDG and indicated that F-18-FIMP may be a safe PET probe for use in humans. F-18-FIMP may provide improved specificity for tumor diagnosis, compared to F-18-FDG, F-18-FET, and C-11-MET. This probe may be suitable for PET imaging for glioblastoma and the early-phase monitoring of cancer therapy outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available